Workshop
One-day hands-on workshop by M&S Decisions focused on translational mechanistic modeling for FiH safe starting dose selection, with practical case examples from T cell engagers and other bispecific antibodies.
Pharmacometricians, modeling scientists and students who seek to gain in-depth knowledge of bispecific antibody drug development, with emphasis on pharmacokinetics, pharmacodynamics and practical skills in quantitative systems pharmacology modeling
Laptop
Functional browser
Join us for a one-day workshop hosted by M&S Decisions, to focus on translational mechanistic modeling in support of First-in-Human (FiH) safe starting dose selection.
The topic addressed in the workshop is of utmost importance, given the intricacies in pharmacokinetics and pharmacodynamics, and the corresponding unique safety challenges inherent to this multi-component therapeutic modality. The mechanistic modeling approach presented, which we will examine in a practical, hands-on manner, represents a must-have element in CTA/IND submissions.
The case examples which we will be focusing on during the workshop are based on the actual modeling applications in the development of T cell engagers (TCE) and other types of bispecific antibodies, although the overall methodology becomes generally for other types of novel multi-component therapeutics, such as autologous and allogenic cell therapies, antibody-drug and -oligo conjugates, targeted lipid or polymer nanoparticles with encapsulated drug, PROTACs etc.
In fact, our session will take participants through various modeling approaches, from a more empirically driven workflow to estimate FiH starting dose using MABEL criteria, to a mechanistically oriented translational approach using a quantitative systems pharmacology (QSP) modeling workflow. Work will be held on an integrative cloud ecosystem, “Simurg”, and a set of packages from the R programming environment.
The workshop covers the following key elements of FiH dose selection for bispecific antibodies:
- Therapeutic utility and challenges in the development of complex, multi-component biologics and cellular therapies;
- Implementation of FiH dose selection based on minimal anticipated biological effect level (MABEL) criteria;
- Model-based analysis of in vitro cytotoxicity data, while accommodating for diverse experimental conditions (incubation time, E:T ratio, various cell lines, etc.) using conventional fitting algorithms (i.e., NONMEM, Monolix, nlmixr) implemented in Simurg ecosystem;
- Development of a translational QSP model to predict exposure-efficacy and exposure-safety relationships in patients – from exploratory data analysis to advanced diagnostics;
- Generation of virtual patient populations which take into account variabilities in PK and in diverse disease states and immunological conditions;
- Implementation of model-informed selection of pharmacologically active and safe starting doses for bispecific antibodies, based on a case study with T cell engagers (TCE);
- Regulatory requirements for inclusion of the MIDD approaches to support CTA/IND applications.
